ABCC1 and hepatocellular carcinoma: It has been reported that miR-326 and miR-133a reduce adriamycin resistance of human hepatoma HepG2 cells through downregulating ABCC1 expression [18]; miR-1291 could modulate cellular drug disposition through direct targeting ABCC1 in PANC-1 cells [19].